Thielemans K - Search Results

1

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection.

Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, van den Ham HJ, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, Brander C, Thielemans K, Martínez-Picado J, Plana M, García F; iHIVARNA consortium. Leal L, et al. Among authors: thielemans k. AIDS. 2018 Nov 13;32(17):2533-2545. doi: 10.1097/QAD.0000000000002026. AIDS. 2018. PMID: 30289805 Free PMC article. Clinical Trial.

2

Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.

Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Bakkus MH, et al. Among authors: thielemans k. Blood. 1992 Nov 1;80(9):2326-35. Blood. 1992. PMID: 1421403 Free article.

3

Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement studies.

Van Riet I, Heirman C, Lacor P, De Waele M, Thielemans K, Van Camp B. Van Riet I, et al. Among authors: thielemans k. Br J Haematol. 1989 Nov;73(3):289-95. doi: 10.1111/j.1365-2141.1989.tb07742.x. Br J Haematol. 1989. PMID: 2605118

4

Production and characterization of bispecific single-chain antibody fragments.

De Jonge J, Brissinck J, Heirman C, Demanet C, Leo O, Moser M, Thielemans K. De Jonge J, et al. Among authors: thielemans k. Mol Immunol. 1995 Dec;32(17-18):1405-12. doi: 10.1016/0161-5890(95)00089-5. Mol Immunol. 1995. PMID: 8643110

5

In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.

De Jonge J, Heirman C, de Veerman M, Van Meirvenne S, Moser M, Leo O, Thielemans K. De Jonge J, et al. Among authors: thielemans k. J Immunol. 1998 Aug 1;161(3):1454-61. J Immunol. 1998. PMID: 9686611

6

Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K. De Veerman M, et al. Among authors: thielemans k. J Immunol. 1999 Jan 1;162(1):144-51. J Immunol. 1999. PMID: 9886380

7

Dendritic cells transduced with viral interleukin 10 or Fas ligand: no evidence for induction of allotolerance in vivo.

Buonocore S, Van Meirvenne S, Demoor FX, Paulart F, Thielemans K, Goldman M, Flamand V. Buonocore S, et al. Among authors: thielemans k. Transplantation. 2002 Jan 15;73(1 Suppl):S27-30. doi: 10.1097/00007890-200201151-00010. Transplantation. 2002. PMID: 11810058 Review.

8

Efficient genetic modification of murine dendritic cells by electroporation with mRNA.

Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, Thielemans K. Van Meirvenne S, et al. Among authors: thielemans k. Cancer Gene Ther. 2002 Sep;9(9):787-97. doi: 10.1038/sj.cgt.7700499. Cancer Gene Ther. 2002. PMID: 12189529

9

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, Van Riet I, Thielemans K. Tuyaerts S, et al. Among authors: thielemans k. J Immunol Methods. 2002 Jun 1;264(1-2):135-51. doi: 10.1016/s0022-1759(02)00099-6. J Immunol Methods. 2002. PMID: 12191517

10

Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.

Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, van der Bruggen P, Thielemans K. Breckpot K, et al. Among authors: thielemans k. J Gene Med. 2003 Aug;5(8):654-67. doi: 10.1002/jgm.400. J Gene Med. 2003. PMID: 12898635

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

350 results

Search Page